Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.


Journal

Journal of biophotonics
ISSN: 1864-0648
Titre abrégé: J Biophotonics
Pays: Germany
ID NLM: 101318567

Informations de publication

Date de publication:
07 2019
Historique:
received: 14 10 2018
revised: 12 01 2019
accepted: 13 01 2019
pubmed: 18 1 2019
medline: 9 9 2020
entrez: 18 1 2019
Statut: ppublish

Résumé

Actinic keratosis (AK) corresponds to the earliest stage of in situ squamous cell carcinoma and arises on chronically sun-exposed skin. Around the clinically evident AKs, the apparently healthy epidermis may contain different grades of atypia that can be detected by noninvasive imaging techniques such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT). Subclinical actinic keratosis (sAK) has captured increasing interest as a potential target of field therapies. The aim of this study was to evaluate in vivo the changes in the field cancerization undergoing treatment with topical ingenol mebutate by combining RCM and OCT. Twenty patients with field cancerization of the face and scalp were treated with ingenol mebutate gel (150 mcg/g) for three consecutive days on an area of 25 cm

Identifiants

pubmed: 30653833
doi: 10.1002/jbio.201800391
doi:

Substances chimiques

3-ingenyl angelate 0
Diterpenes 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e201800391

Subventions

Organisme : Leo Pharma
Pays : International

Informations de copyright

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Auteurs

Cristel Ruini (C)

Department of Dermatology and Allergy, University Hospital LMU Munich, Munich, Germany.
Department of Dermatology, Clinic for Dermatology and Allergy, Munich Municipal Hospital Group, Munich, Germany.

Daniela Hartmann (D)

Department of Dermatology and Allergy, University Hospital LMU Munich, Munich, Germany.
Department of Dermatology, Clinic for Dermatology and Allergy, Munich Municipal Hospital Group, Munich, Germany.

Mike Bastian (M)

Medical Advisory Department, LEO Pharma GmbH, Neu-Isenburg, Germany.

Thomas Ruzicka (T)

Department of Dermatology and Allergy, University Hospital LMU Munich, Munich, Germany.

Lars E French (LE)

Department of Dermatology and Allergy, University Hospital LMU Munich, Munich, Germany.

Carola Berking (C)

Department of Dermatology and Allergy, University Hospital LMU Munich, Munich, Germany.

Tanja von Braunmühl (T)

Department of Dermatology and Allergy, University Hospital LMU Munich, Munich, Germany.
Department of Dermatology, Clinic for Dermatology and Allergy, Munich Municipal Hospital Group, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH